1. Савченко В.Г., Паровичникова Е.Н. Острые лейкозы // Клиническая онкогематология: руководство для врачей. Под ред. Волковой М.А.. 2-е изд., перераб. и доп. 2007. P. 409-502.
2. Паровичникова Е.Н. et al. Клинический протокол ОМЛ-01.10 по лечению острых миелоидных лейкозов взрослых // Программное лечение заболеваний крови, под ред. Савченко В.Г. М.: Практика, 2012. P. 153-207.
3. Shallis R.M. et al. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. // Blood Rev. 2019. Vol. 36. P. 70-87.
4. Swerdlow S.H. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms // Blood. 2016.
5. Arber D.A. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia // Blood. American Society of Hematology, 2016. Vol. 127, № 20. P. 2391-2405.
6. Grimwade D., Hills R.K. Independent prognostic factors for AML outcome. // Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2009. P. 385-395.
7. Dohner H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel // Blood. 2017. Vol. 129, № 4. P. 424-447.
8. Acute Myeloid Leukemia. National Comprehensive Cancer Network (NCCN) Guidelines. 2-2020. [Electronic resource]. URL: https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf.
9. Kulsoom B. et al. Clinical presentation of acute myeloid leukaemia - A decade-long institutional follow-up. // J. Pak. Med. Assoc. 2017. Vol. 67, № 12. P. 1837-1842.
10. Godley L.A. Inherited predisposition to acute myeloid leukemia. // Semin. Hematol. 2014. Vol. 51, № 4. P. 306-321.
11. Oken M.M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group // Am. J. Clin. Oncol. 1982. Vol. 5, № 6. P. 649-655.
12. Roila F. et al. Intra and interobserver variability in cancer patients’ performance status assessed according to Karnofsky and ECOG scales // Ann. Oncol. Oxford University Press (OUP), 1991. Vol. 2, № 6. P. 437-439.
13. Wass M. et al. Value of different comorbidity indices for predicting outcome in patients with acute myeloid leukemia // PLoS One. 2016. Vol. 11, № 10. P. e0164587.
14. Mohammadi M. et al. The impact of comorbid disease history on all-cause and cancerspecific mortality in myeloid leukemia and myeloma - a Swedish population-based study. // BMC Cancer. 2015. Vol. 15. P. 850.
15. Agis H. et al. A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis. // Ann. Hematol. 2002. Vol. 81, № 2. P. 90-95.
16. Avni B. et al. Clinical implications of acute myeloid leukemia presenting as myeloid sarcoma. // Hematol. Oncol. 2012. Vol. 30, № 1. P. 34-40.
17. Dohner H. et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet // Blood. Blood, 2010. Vol. 115, № 3. P. 453-474.
18. Ku G.H. et al. Venous thromboembolism in patients with acute leukemia: Incidence, risk factors, and effect on survival // Blood. 2009. Vol. 113, № 17. P. 3911-3917.
19. Lahoti A. et al. Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome // Cancer. 2010. Vol. 116, № 17. P. 4063-4068.
20. Fang R.C., Aboulafia D.M. HIV infection and myelodysplastic syndrome/acute myeloid leukemia // HIV-Associated Hematological Malignancies. 2016. P. 133-144.
21. Freeman A.J. et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. // Hepatology. 2001. Vol. 34, № 4 Pt 1. P. 809-816.
22. Ribas A. et al. How important is hepatitis C virus (HCV)-infection in persons with acute leukemia? // Leuk. Res. 1997. Vol. 21, № 8. P. 785-788.
23. Rossi D. et al. Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naive patients with chronic lymphocytic leukemia // Leuk. Lymphoma. 2009. Vol. 50, № 4. P. 604-611.
24. Lam M.T. et al. Herpes simplex infection in acute myelogenous leukemia and other hematologic malignancies: a prospective study. // Cancer. 1981. Vol. 48, № 10. P. 21682171.
25. Bernson E. et al. Cytomegalovirus serostatus affects autoreactive NK cells and outcomes of IL2-based immunotherapy in acute myeloid leukemia // Cancer Immunol. Res. American Association for Cancer Research Inc., 2018. Vol. 6, № 9. P. 1110-1119.
26. Guan H. et al. Correlations between Epstein-Barr virus and acute leukemia // J. Med. Virol. John Wiley and Sons Inc., 2017. Vol. 89, № 8. P. 1453-1460.
27. Elmaagacli A.H., Koldehoff M. Cytomegalovirus replication reduces the relapse incidence in patients with acute myeloid leukemia // Blood. American Society of Hematology, 2016. Vol. 128, № 3. P. 456-459.
28. Averbuch D. et al. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: Guidelines of the 4th European conference on Infections in Leukemia (ECIL-4, 2011) // Haematologica. Ferrata Storti Foundation, 2013. Vol. 98, № 12. P. 1836-1847.
29. Averbuch D. et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: Summary of the 2011 4th European Conference on Infections in Leukemia // Haematologica. Ferrata Storti Foundation, 2013. Vol. 98, № 12. P. 1826-1835.
30. Leahy M.F., Mukhtar S.A. From blood transfusion to patient blood management: a new paradigm for patient care and cost assessment of blood transfusion practice. // Intern. Med. J. 2012. Vol. 42, № 3. P. 332-338.
31. Olsen R.J. et al. Acute leukemia immunohistochemistry: a systematic diagnostic approach. // Arch. Pathol. Lab. Med. 2008. Vol. 132, № 3. P. 462-475.
32. Bene M.C. et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). // Leukemia. 1995. Vol. 9, № 10. P. 1783-1786.